Abstract: A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs and/or naltrexone.

Abstract: A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO).

Abstract: A compounded transdermal cream for the topical administration of a compounded therapy includes a first active agent selected from the group consisting of nabumetone in an amount between approximately 5.0% and approximately 25% by weight of the transdermal cream and amitriptyline in an amount between approximately 0.5% and approximately 4.0% by weight of the transdermal cream; a second active agent comprising a nerve depressant in an amount between approximately 5.0% and 15.0% by weight of the transdermal cream, wherein the nerve depressant is gabapentin; a third active agent comprising a local anesthetic in an amount between approximately 1.0% and approximately 7.0% by weight of the transdermal cream, wherein the local anesthetic comprises lidocaine and prilocaine; and dimethyl sulfoxide (DMSO).

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as streptomycin and one or more of colistimethate, clindamycin, mupirocin, or levofloxacin.

Abstract: A method of managing non-infective nasal symptoms may include formulating a topical composition for nasal administration. The formulation may include theophylline and sodium citrate. The formulation may also include a steroid, such as budesonide. The topical composition may be administered nasally.

Abstract: A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes cefixime combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue.

Abstract: A compounded capsule may include cannabidiol powder for combining with a solution, cream, gel, suspension or ointment for administration to a skin surface. The compounded capsule may also include xylitol powder.

Abstract: A method of compounding a topical cream includes combining ingredients including lidocaine and prilocaine, 2.5%/2.5%, cream, lidocaine hydrochloride, 4%, topical solution; and mixing the ingredients to generate a cream.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, kits comprising compounded compositions, containers comprising compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions comprising an anti-fungal agent and methods of using a compounded composition to treat or prevent a fungal infection or a suspected fungal infection. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A compounded capsule may include cannabidiol powder for combining with a solution, cream, gel, suspension or ointment for administration to a skin surface. The compounded capsule may also include xylitol powder.

Abstract: A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.

Abstract: A dry formulation may include one or more active agents including one or more anti-infective agents such as an anti-bacterial agent, anti-fungal agent, or other anti-active agent. The dry formulation may be prepared for administration by mixing the dry formulation with a diluent. In one example, the diluent is a hydrocortisone and acetic acid solution or a sodium chloride solution. The combined preparation may be administered to the ear or skin to treat or prevent an infection.

Abstract: A method of treating or preventing a bacterial infection of a subject may include combining levofloxacin and a diluent to form a treatment solution and topically administering the treatment solution to the subject to bath a skin area with the treatment solution. The treatment solution may include levofloxacin oral solution.

Abstract: A topical cream may include urea and one or more additional active agents such as fluticasone, itraconazole, and mupirocin. The topical cream may be formulated as a lotion, gel, ointment, foam, cream, or emulsion.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more antimicrobial agents such as mupirocin.

Abstract: Supplying a medication for use with a medication delivery system includes supplying a liquid medication composition into an interior volume of a drug chamber and dispensing the drug chamber to a patient or caregiver. The drug chamber may include a fitting for coupling to a corresponding fitting of a transfer module and a drug port. The transfer module may also include a transfer port configured to align with the drug port when the drug chamber and transfer module are coupled at their fittings. The transfer module may be operable to open the drug port to allow transfer of a portion of the liquid medication composition through the transfer port into a separate dose chamber.

Abstract: A method of treating a bacterial infection of a subject includes topically administering a topical composition that includes ceftriaxone for injection powder combined with a carrier. The topical composition may be administered by contacting a tissue surface of the subject to be treated with the topical composition such as skin or mucosal tissue.

Abstract: A method of producing a compounded medication may include formulating a compounded transdermal cream that includes combining a diclofenac sodium solution and a lidocaine and prilocaine cream. The diclofenac sodium solution may be combined in an amount providing a diclofenac concentration of between approximately 0.1% and approximately 0.75% by weight of the compounded transdermal cream. The lidocaine and prilocaine cream may be combined in an amount providing an approximate equivalent concentration of each of lidocaine and prilocaine between approximately 1.5% and approximately 2.25% by weight of the compounded transdermal cream.

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as mupirocin.